The stock price of Geron Corp. (NASDAQ: GERN) has jumped by 6.06 compared to previous close of 4.29. Despite this, the company has seen a fall of -1.09% in its stock price over the last five trading days. businesswire.com reported 2024-07-26 that FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of Myelodysplastic Syndromes (MDS) to recommend RYTELO™ (imetelstat) as a Category 1 and 2A treatment of symptomatic anemia in patients with lower-risk MDS.
Is It Worth Investing in Geron Corp. (NASDAQ: GERN) Right Now?
Moreover, the 36-month beta value for GERN is 0.48. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GERN is 500.46M and currently, short sellers hold a 8.92% of that float. On July 26, 2024, GERN’s average trading volume was 11.61M shares.
GERN’s Market Performance
The stock of Geron Corp. (GERN) has seen a -1.09% decrease in the past week, with a 2.25% rise in the past month, and a 27.81% gain in the past quarter. The volatility ratio for the week is 4.29%, and the volatility levels for the past 30 days are at 4.78% for GERN. The simple moving average for the past 20 days is -0.07% for GERN’s stock, with a 57.61% simple moving average for the past 200 days.
Analysts’ Opinion of GERN
Many brokerage firms have already submitted their reports for GERN stocks, with Robert W. Baird repeating the rating for GERN by listing it as a “Neutral.” The predicted price for GERN in the upcoming period, according to Robert W. Baird is $4.50 based on the research report published on April 30, 2024 of the current year 2024.
TD Cowen, on the other hand, stated in their research note that they expect to see GERN reach a price target of $10. The rating they have provided for GERN stocks is “Buy” according to the report published on April 29th, 2024.
Needham gave a rating of “Buy” to GERN, setting the target price at $5 in the report published on March 15th of the current year.
GERN Trading at 5.72% from the 50-Day Moving Average
After a stumble in the market that brought GERN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.79% of loss for the given period.
Volatility was left at 4.78%, however, over the last 30 days, the volatility rate increased by 4.29%, as shares surge +2.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.18% upper at present.
During the last 5 trading sessions, GERN fell by -0.65%, which changed the moving average for the period of 200-days by +152.49% in comparison to the 20-day moving average, which settled at $4.56. In addition, Geron Corp. saw 115.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GERN starting from GRETHLEIN ANDREW J, who sale 674,348 shares at the price of $4.56 back on Jul 08 ’24. After this action, GRETHLEIN ANDREW J now owns 0 shares of Geron Corp., valued at $3,073,004 using the latest closing price.
Kapur Anil, the EVP, Corp Strategy & CCO of Geron Corp., sale 421,875 shares at $4.64 during a trade that took place back on Jun 10 ’24, which means that Kapur Anil is holding 0 shares at $1,959,609 based on the most recent closing price.
Stock Fundamentals for GERN
Current profitability levels for the company are sitting at:
- -403.82 for the present operating margin
- -57.11 for the gross margin
The net margin for Geron Corp. stands at -387.3. The total capital return value is set at -0.59. Equity return is now at value -60.04, with -44.41 for asset returns.
Based on Geron Corp. (GERN), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -2.19. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is -36.9.
Currently, EBITDA for the company is -192.91 million with net debt to EBITDA at 0.51. When we switch over and look at the enterprise to sales, we see a ratio of 4966.43. The receivables turnover for the company is 0.32for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.67.
Conclusion
To wrap up, the performance of Geron Corp. (GERN) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
